Background: An effective dengue vaccine should ideally induce broadly neutralizing antibody (nAb) responses against all 4 dengue virus (DENV) serotypes.
Methods: We characterized the specificity and breadth of the nAb response to TAK-003, a live-attenuated tetravalent dengue vaccine, in serum samples from phase 2 and 3 clinical trials.
Results: Microneutralization tests using postvaccination serum showed comparable neutralization against diverse DENV-1-4 genotypes. Reporter virus particle neutralization assays after depletion of anti-DENV-2 nAbs demonstrated that the nAb response to DENV-1, -3, and -4 comprises both type-specific (TS) and cross-reactive (CR) nAbs.
Conclusions: Therefore, TAK-003 induces broad tetravalent TS and CR nAb responses.
Keywords: TAK-003; dengue vaccine; dengue virus; neutralizing antibody response; type-specific.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.